Literature DB >> 1648927

Molecular and cellular mechanisms of receptor-mediated endocytosis.

V I Brown1, M I Greene.   

Abstract

In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors and ligands are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes. The internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of certain viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Although endocytosis is common to all nucleated eukaryotic cells, the factors that regulate these receptor-mediated endocytic pathways are not fully understood. Defective receptors that are not capable of undergoing normal endocytosis can lead to certain disease states, as in the case of familial hypercholesteremia (FH). This review has three objectives: (i) to describe the different routes that receptors and ligands follow after internaliation; (ii) to describe the potential mechanisms which regulate the initiation and subsequent sorting of receptors and ligands so they reach their final destination; and (iii) to describe the potential functions of receptor-mediated endocytosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648927     DOI: 10.1089/dna.1991.10.399

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  18 in total

1.  Recycling and resensitization of delta opioid receptors.

Authors:  N Trapaidze; I Gomes; M Bansinath; L A Devi
Journal:  DNA Cell Biol       Date:  2000-04       Impact factor: 3.311

Review 2.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

Review 3.  Cellular elements of the blood-brain barrier.

Authors:  Jorge Correale; Andrés Villa
Journal:  Neurochem Res       Date:  2009-10-25       Impact factor: 3.996

4.  Photodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells.

Authors:  T Maisch; C Bosl; R-M Szeimies; N Lehn; C Abels
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14.

Authors:  D A Shepard; B A Heinz; R R Rueckert
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

6.  Thyrotropin internalization is directed by a highly conserved motif in the seventh transmembrane region of its receptor.

Authors:  Y Shi; M Zou; P Ahring; S T Al-Sedairy; N R Farid
Journal:  Endocrine       Date:  1995-06       Impact factor: 3.633

7.  Failure of immunization with trypanosome endocytotic vesicle membrane proteins to provide nonvariant immunoprotection against Trypanosoma brucei.

Authors:  S Z Shapiro
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

8.  Effect of chlorpromazine on kinetics of injected monoclonal antibody in MoAb-induced glomerular injury.

Authors:  N Takashima; H Kawachi; T Oite; S Nishi; M Arakawa; F Shimizu
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

9.  Phosphorylation and internalization of gp130 occur after IL-6 activation of Jak2 kinase in hepatocytes.

Authors:  Y Wang; G M Fuller
Journal:  Mol Biol Cell       Date:  1994-07       Impact factor: 4.138

10.  Human cell receptor CD46 is down regulated through recognition of a membrane-proximal region of the cytoplasmic domain in persistent measles virus infection.

Authors:  A Hirano; S Yant; K Iwata; J Korte-Sarfaty; T Seya; S Nagasawa; T C Wong
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.